 |
Products Cover Multiple Fields, Awarded for Innovation
The exhibited products cover oncology, autoimmune diseases, and metabolic disorders. Among them, several blockbuster drugs, including albumin-bound paclitaxel, bevacizumab, infliximab, enzalutamide, aflibercept, liraglutide, and semaglutide, attracted extensive inquiries from visiting clients.
In terms of the R&D pipeline, the company highlighted multiple global innovative drug pipelines, including the cancer cachexia drug GB18 project, the lupus erythematosus drug GB19/GB26 project, the ophthalmic drug GB10 project, and the autoimmune drug GB20/GB24 project. The clinical progress of two Phase III projects—long-acting GC and interferon inhalation solution GB05—also garnered attention.
In recent years, the company’s continuous accumulation in technology platforms and innovative achievements has helped it win the “CPHI R&D Innovation Award.” This award, jointly presented by the organizers and authoritative institutions, evaluates companies based on multiple dimensions such as scientific research innovation capabilities, clinical translation breakthroughs, technology integration applications, and market influence. It serves as a summary of industrial innovation achievements and an insight into future pharmaceutical R&D trends and directions.
Gathering at Forums, Accelerating International Business Connections
At this conference, Kexing Biopharm’s BD team actively participated in multiple high-end forums and industry roundtable meetings focused on drug exports, engaging in in-depth discussions on cutting-edge topics such as the overseas commercialization of Chinese biopharmaceuticals. While showcasing the achievements of the company’s export platform, these activities provided important industry perspectives and references for further optimizing export pathways and seizing global market opportunities.
On the evening of June 15, Kexing Biopharm invited clients and partners from multiple countries to gather together for relaxed yet in-depth exchanges on market dynamics, cooperation prospects, and future plans, laying a foundation of mutual trust and win-win collaboration for subsequent partnerships.
CPHI serves as a deep showcase and resource connection for Kexing Biopharm in the global pharmaceutical market. In the future, the company will continue to deepen its global presence and work hand in hand with partners worldwide to bring more high-quality products to a broader international market.